Ireland
--:--IST
Active, not recruiting Not applicable

An Early Feasibility Study Evaluation of an Implant Free Interatrial Shunt to Improve Heart Failure

NCT06859970 · tracked via the Priya Life Science USA tracker
Sponsor
InterShunt Technologies, Inc
Phase
Not applicable
Started
2025-05-15
Last updated
2026-05-27

Condition(s) studied

Heart FailureHeart Failure NYHA Class IIIHeart Failure With Reduced Ejection FractionAmbulatory Heart Failure, NYHA Class IV

Investigational drug(s) / intervention(s)

PAS-C System

PAS-C System: All patients will undergo catheterization with the PAS-C System to create an interatrial shunt to reduce left atrial pressure in the heart.

Study summary

The purpose of this early feasibility study is to evaluate the safety and feasibility of the device for percutaneous shunting of the interatrial septum and improvement of heart failure related symptoms. The primary goal is to determine if the device is safe to use. The findings from this study may be used to refine the intended patient population, the design of the device, or develop a subsequent randomized study.

Eligibility

Sex
ALL
Min age
40 Years
Max age
85 Years
Healthy volunteers
No
Inclusion Criteria: * NYHA Class II at screening with a prior history of greater than NYHA Class II, OR NYHA Class III at screening, OR ambulatory Class IV at screening: with documented medical history of heart failure for at least 6 months prior to the screening visit. * At least one hospitalization for heart failure OR treatment with IV diuretics for heart failure OR elevated BNP in the prior 12 months. * Receiving maximally tolerated guideline directed medical therapy for Heart Failure management. * LVEF ≥ 20% and ≤ 40% according to baseline echocardiography. * Resting right heart catheterization demonstrates elevated PCWP compared to right atrial pressure. Exclusion Criteria: * Any of the following within the prior 6 months: Stroke, thromboembolism, severe or advanced heart failure such as Stage D heart failure, non-ambulatory NYHA Class IV, cardiac index less than 1.8 L/min/m2, LVEDD \> 8 cm, or received inotropic therapy for LVEF less than 20%. * Any of the following within the prior 3 months: Myocardial infarction percutaneous cardiac intervention, CABG, on cardiac transplant list, cardiac resynchronization therapy implant, AICD implant, or indicated for coronary revascularization at the time of enrollment. * Transseptal procedure or percutaneous cardiac intervention planned within the next 6 months. * Chronic pulmonary disease requiring continuous home oxygen or hospitalization within the prior 12 months for pulmonary disease. * Patent foramen ovale (PFO) device or atrial septal defect (ASD) device. * BMI \> 40. * Anatomic anomaly that precludes creation of interatrial shunt.

Primary outcome measure(s)

  • Measure of major safety events in the periprocedural timeframe — Through one month post procedure
    Proportion of subjects who experience a major adverse cardiac or cerebrovascular event or systemic embolization

Trial sites (6)

FacilityCityRegionStatus
St. Bernard's Healthcare Jonesboro Arkansas
Los Robles Health System Thousand Oaks California
Ascension St. Vincent Hospital Indianapolis Indiana
Christ Hospital Cincinnati Ohio
The Ohio State University Columbus Ohio
Methodist Healthcare San Antonio Texas
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06859970 on ClinicalTrials.gov ↗ ← All trials in the USA